These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29857173)

  • 1. The trans-[Ru(PPh
    Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
    J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Coordination Mode of Acylthiourea Ligands in Half-Sandwich Ru(II) Complexes and Their Cytotoxic Evaluation.
    Cunha BN; Luna-Dulcey L; Plutin AM; Silveira RG; Honorato J; Cairo RR; de Oliveira TD; Cominetti MR; Castellano EE; Batista AA
    Inorg Chem; 2020 Apr; 59(7):5072-5085. PubMed ID: 32208661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.
    Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M
    Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
    Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
    Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoencapsulation of Ruthenium Complex Ru(ThySMet): A Strategy to Improve Selective Cytotoxicity against Breast Tumor Cells in 2D and 3D Culture Models.
    Becceneri AB; Fuzer AM; Lopes AC; da Silva PB; Plutin AM; Batista AA; Chorilli M; Cominetti MR
    Curr Drug Discov Technol; 2024; 21(2):e060623217687. PubMed ID: 37282638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of the Ruthenium Complex [Ru(GA)(dppe)
    Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
    Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
    Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
    Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
    Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
    J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.
    Zhang GD; Wang MM; Su Y; Fang H; Xue XL; Liu HK; Su Z
    J Inorg Biochem; 2024 Jul; 256():112574. PubMed ID: 38677004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
    Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
    Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells.
    Mansour N; Bodman-Smith K; Khnayzer RS; Daher CF
    Chem Biol Interact; 2021 Feb; 336():109317. PubMed ID: 33197429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium(II)-diphosphine complexes containing acylthiourea ligands are effective against lung and breast cancers.
    Grawe GF; Oliveira KM; Leite CM; de Oliveira TD; Honorato J; Ferreira AG; Castellano EE; Cominetti MR; Correa RS; Batista AA
    Dalton Trans; 2022 Jan; 51(4):1489-1501. PubMed ID: 34989381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
    Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
    Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparasitic activities of novel ruthenium/lapachol complexes.
    Barbosa MI; Corrêa RS; de Oliveira KM; Rodrigues C; Ellena J; Nascimento OR; Rocha VP; Nonato FR; Macedo TS; Barbosa-Filho JM; Soares MB; Batista AA
    J Inorg Biochem; 2014 Jul; 136():33-9. PubMed ID: 24727183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of ruthenium-N,N-disubstituted-N'-acylthioureas complexes.
    de Oliveira TD; Plutín AM; Luna-Dulcey L; Castellano EE; Cominetti MR; Batista AA
    Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111106. PubMed ID: 32600709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.